Renal cell carcinoma (RCC) is the ninth most common cancer in humans. In the last decade, a better understanding of the molecular mechanisms underlying tumorigenesis, angiogenesis, cell growth and proliferation, and the discovery of molecular alterations involved in RCC pathogenesis, have led to the identification of molecular targets of great clinical interest that have revolutionized the treatment of metastatic RCC (mRCC). Sunitinib, pazopanib and bevacizumab plus interferon-alpha remain the standard first-line treatments: these agents have significantly improved prognosis in mRCC. Everolimus, axitinib and sorafenib have demonstrated significant efficacy as second-line therapies. Nivolumab and cabozantinib are the most promising new-generation agents in the treatment of RCC. All of these agents, given in sequence, have extended life expectancy of RCC patients from 13 months in the cytokine era to over 20 months. Despite this improvement, it is not easy to establish the right sequence in which to administered different agents because there aren't yet ways to identify or select patients likely to benefit or those who could be resistant to specific drugs. In this review we present clinical data on the sequential treatment in RCC and discuss key factors that need to be considered when physicians make treatment decisions for individual patients.
Introduction
Renal cell carcinoma (RCC) is the ninth most common human cancer. In the United States about 62,700 new cases are expected to occur in 2016, associated with more than 14,240 deaths [1] . Approximately 25% of patients with RCC present with locally advanced or metastatic disease at diagnosis, and about 20-40% of patients with confined primary tumor will eventually develop metastatic disease [2, 3] . Until 2005, interleukin-2 (IL-2) and interferon-alpha (IFN-α) were the standards of care in the treatment of metastatic RCC (mRCC). These therapies were associated with few durable responses and considerable doselimiting toxicities [4] . More recently, a better understanding of the molecular mechanisms underlying tumorigenesis, angiogenesis, cell growth and proliferation, and the discovery of the molecular alterations involved in RCC pathogenesis, have allowed the identification of several molecular targets of great therapeutic interest [5] [6] [7] [8] . These include the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), the mammalian target of rapamycin (mTOR) signaling pathway, the hypoxia inducible factors (HIFs) and the fibroblast growth factor (FGF) and its receptor (FGFR). Identification of these molecular targets has led to the development of systemic treatments that have been incorporated into the treatment paradigm in mRCC, such as the humanized anti-VEGF monoclonal antibody bevacizumab in combination with IFN-α, the multitargeted tyrosine kinase inhibitors (TKIs) sorafenib, sunitinib, pazopanib and axitinib, and two kinase inhibitors of mTOR, temsirolimus and everolimus. The introduction of these agents has changed the treatment landscape and prognosis of mRCC patients; they have been associated with progression-free survival (PFS) and overall survival (OS) benefit, while very long-term disease control has also been re-ported [9] . Nevertheless, resistance to first-line treatment occurs after a median time of 8-11 months, necessitating a change of treatment in the majority of cases [10, 11] . Most of the approved targeted therapies have shown efficacy in relapsed disease. Therefore, an important consideration is the sequence in which these agents should be used. The sequencing question becomes of primary importance when multiple treatments are developed in a short period of time or new drugs are licensed before others have a definite place in the therapeutic armamentarium; this is also complicated by the lack of studies directly comparing new agents as well as uncertainty around the association of disease progression with RECIST criteria and the need for change in therapy. In this article, we focus on the sequential treatment of mRCC and discuss the main factors that physicians need to take into account when making therapeutic decisions.
First-line therapy in mRCC
Several new anti-VEGF drugs have been approved for first-line treatment in mRCC. These agents have improved patient outcomes compared with the previous cytokines-based standard of care (Table 1) . Current evidence-based guidelines [3] recommend three agents as first-line treatment for patients with goodintermediate risk according to Memorial Sloan Kettering Cancer Center (MSKCC) risk groups: bevacizumab (combined with IFN-α), sunitinib and pazopanib. Firstline temsirolimus has demonstrated activity in patients with poor prognosis [12] . Bevacizumab combined with IFN-α significantly improved PFS compared with IFN-α alone in mRCC [13] . Due to the need for frequent hospital visits associated with this combination and the toxicity of IFN-α, orally-administered sunitinib and pazopanib have become more popular in everyday practice. Sunitinib is an oral, small-molecule, multi-targeted receptor TKI that was approved for first-line treatment of RCC based on data from a phase III trial showing its superiority over IFN-α [14] . In this trial, 750 patients with previously untreated mRCC were enrolled and randomized to receive oral sunitinib (50 mg once daily for 4 weeks, followed by 2 weeks' rest) or subcutaneous IFN-α (9 MU three times weekly). Sunitinib significantly improved PFS compared with IFN-α (11 vs 5 months, hazard ratio [HR] 0.42, 95% confidence interval [CI] 0.32-0.54; p<0.001). Sunitinib was also associated with a higher objective response rate (ORR) (31% vs 6%; p<0.001). In general, patients treated with sunitinib reported significantly better quality of life than those in the IFN-α group (p<0.001). Pazopanib is an oral angiogenesis inhibitor targeting VEGFR, platelet-derived growth factor receptor (PDGFR) and c-Kit; it was first tested in a randomized placebocontrolled phase III trial, with 54% treatment-naïve and 46% cytokine pre-treated patients [15, 16] . In this study, median PFS was significantly prolonged in pazopanib recipients compared with placebo in the overall study population (9.2 vs 4.2 months, HR 0.46, 95%CI 0.34-0.62; p<0.0001), treatment-naïve patients (11.1 vs 2.8 months, HR 0.40, 95%CI 0.27-0.60; p<0.0001), and cytokine-pretreated patients (7.4 vs 4.2 months, HR 0.54, 95%CI 0.35-0.84; p<0.001). The ORR was 30% with pazopanib compared with 3% with placebo. The most common adverse events (AEs) were diarrhea, hypertension, nausea, anorexia, vomiting and hair color changes. Pazopanib was compared head-to-head with sunitinib in a randomized non-inferiority trial in the first-line setting (COMPARZ trial) [17] . This study showed that pazopanib was non-inferior to sunitinib with respect to PFS (HR for progression of disease or death from any cause 1.05, 95%CI 0.90-1.22) (the predefined non-inferiority margin was upper bound of the 95%CI <1.25). OS was similar in patients treated with either of the two agents. Sunitinib versus pazopanib recipients had a higher incidence of fatigue (63% vs 55%), hand-foot syndrome (50% vs 29%) and thrombocytopenia (78% vs 41%), while patients treated with pazopanib had a higher incidence of increased alanine aminotransferase levels (60% vs 43% with sunitinib). A crossover trial (PISCES) was designed to assess patients' preference for pazopanib versus sunitinib [18] ; Sequential medical therapy in renal carcinoma patients with treatment-naïve mRCC were randomized to sequential use of pazopanib for 10 weeks followed by sunitinib for 10 weeks, or vice versa, with a 2-week washout period between treatments. At 22 weeks, significantly more patients preferred pazopanib (70%) over sunitinib (22%), while 8% did not have any preference. These findings underline the importance of a detailed discussion of different toxicity profiles with patients in order to make the appropriate treatment choices. The superiority of anti-VEGFR therapy as initial treatment in mRCC over mTOR inhibition was established by the RECORD-3 trial. In this phase II study, patients were randomized to receive first-line everolimus followed by sunitinib at disease progression or sunitinib in first-line followed by everolimus [19] . The primary endpoint of non-inferiority was not met: median PFS was 7.9 months in patients treated with first-line everolimus compared with 10.7 months in those who had first-line sunitinib; corresponding values for median combined PFS were 21.1 and 25.8 months and for median OS were 22.4 and 32.0 months, showing that sunitinib then everolimus was superior across all measures.
Second-line therapy in mRCC
Multiple agents have been approved for second-line therapy in mRCC based on the results of several phase III studies (Table 2) . Treatment options include sorafenib, axitinib, everolimus and, more recently, nivolumab. Table 2 outlines the current European Society of Medical Oncology (ESMO) guidelines, which will soon be changed to incorporate nivolumab, for which there is data with the highest level of evidence. Sorafenib is a multikinase inhibitor of multiple growth factor receptors such as VEGFR, PDGFr, Flt-3 and c-Kit and Raf-1 (a member of RAF/MEK/ERK signaling pathway). Axitinib is a next-generation TKI, potent and highly selective for VEGF receptors 1, 2 and 3, and everolimus is an mTOR inhibitor. In the phase III AXIS trial, axitinib was compared with sorafenib as second-line treatment in patients with advanced clear cell RCC who had received first-line treatment with sunitinib (54%), cytokines (35%), bevacizumab (8%) or temsirolimus (3%) [20] . Median PFS was 6.7 months with axitinib and 4.7 months with sorafenib (HR 0.665, 95%CI 0.544-0.812; p<0.0001). The most common adverse events were diarrhea, hypertension, and fatigue in axitinib recipients, and diarrhea, hand-foot syndrome and alopecia in the sorafenib group. These results led to the approval of axitinib for second-line therapy of advanced RCC. The RECORD-1 trial provides data on the use of mTOR inhibitors after VEGFR inhibition-based therapy. In this phase III trial, patients who had received one or two previous treatments were randomized to everolimus or placebo. The results need to be interpreted with caution because only 21% of patients enrolled were receiving pure second-line therapy, progressing after first-line treatment with sunitinib. In this subgroup, patients treated with everolimus had a median PFS of 4.6 versus 1.8 months with placebo; 53% of patients received one TKI and cytokine (PFS 5.2 vs 1.8 months) and 26% were receiving third-line therapy after two TKIs (PFS 4.0 vs 1.8 months) [21, 22] . Nivolumab (BMS-936558) is a fully human, immunoglobulin (Ig) G4 monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor. The major role of PD-1 is to reduce the activity of T cells in peripheral tissues in case of an inflammatory response to infection, and to limit autoimmunity. This translates into a major immune resistance mechanism within the tumor microenvironment. PD-1 has two ligands (PD-1 ligand 1 [PD-L1] and PD-1 ligand 2 [PD-L2]); nivolumab binds to PD-1, preventing its interaction with PD-L1 and PD-L2, disrupting negative signaling to restore T-cell antitumor function [23] . The CheckMate 025 trial was designed to demonstrate OS superiority for nivolumab compared with everolimus in patients with mRCC previously treated with at least one prior TKI (including sunitinib or pazopanib) [24] . Nivolumab improved OS versus everolimus (25.0 vs 19.6 months, HR 0.75; p=0.002); the response to nivolumab was independent of PD-L1 expression. These findings resulted in the recent approval of nivolumab by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). There is controversy about the optimal sequence when choosing second-line therapy. For example, in patients who develop VEGFR TKI-resistance, is it better to continue treatment with a different agent with the same mechanism of action or to overcome cross-resistance by switching to an agent with a different mechanism of action? [25] [26] [27] [28] [29] . The only trial that has provided a direct comparison between second-line agents with different mechanisms of action is the INTORSECT phase III trial [30] . In this study patients with mRCC who had progressed on first-line sunitinib were randomized to receive temsirolimus or sorafenib. There was no significant difference in PFS between the two treatment groups (4.28 vs 3.91 months; p=0.19), while median OS was in favor of sorafenib (16.4 vs 12.3 months; p=0.014) [30] . These results could be interpreted to suggest an advantage for the VEGFR TKI-VEGFR TKI sequence compared with the VEGFR-TKI-mTOR inhibitor (mTORi) sequence, but it does not clarify the controversy because it compares two treatments that are not the best option in the second-line setting. There is no direct comparison between axitinib and everolimus as second-line therapy in mRCC, but data from the two phase III trials (AXIS and RECORD-1) can be used to make an indirect comparison, although the main difference is that in the AXIS trial, axitinib is compared to sorafenib while in the RECORD-1 trial the comparator is placebo. Median PFS with axitinib and everolimus in patients with mRCC progression after first-line with sunitinib was quite similar (4.8 months with axitinib vs 4.6 months with everolimus). In the AXIS trial, one-third of patients had only received prior cytokines and were therefore effectively anti-VEGFR naïve. Conversely, in the RECORD-1 trial, only 21% of patients enrolled were receiving pure second-line therapy, and the remaining patients had received additional therapies prior to everolimus. Finally, in the phase III SWITCH-I trial, patients were randomized to sorafenib followed by sunitinib, or vice versa, on progression or intolerable toxicity [31] . Total PFS was similar in the two treatment arms, demonstrating that clinical benefit was not significantly different based on the order of treatment. Taken together, and in addition to retrospective analyses, the above data do not provide conclusive evidence for one sequence of treatment over another in second-line therapy for mRCC. It is possible that the availability of new data in this area could make the choice between a TKI and an mTOR inhibitor as second-line therapy irrelevant because new standards will soon be introduced in this setting.
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Beyond second-line therapy
Most data relating to third-line treatments and beyond are derived from retrospective studies and subgroup analyses. In a retrospective study of 2,065 patients with mRCC treated in 23 centers in Italy, the sequence VEGF inhibitor (VEGFi)-VEGFi-mTORi was associated with improved survival compared with VEGFi-mTORiVEGFi, particularly in patients with good prognostic risk at diagnosis of metastatic disease, and primary resistance to first-line therapy was a negative predictive and prognostic factor [32] . Subgroup analysis performed within the RECORD-1 trial assessed everolimus as a third-line drug, showing significant PFS benefit versus placebo (4.0 vs 1.8 months, HR 0.32; p<0.01), favoring the TKI-TKI-mTORi sequence [33] . The GOLD trial evaluated a third-line treatment in patients treated with one previous VEGFi-TKI and one previous mTORi: patients received dovitinib (an oral TKI of VEGFR and FGFr) or sorafenib. This trial showed no statistically significant differences between the two agents in terms of PFS (3.6 vs 3.7 months, respectively, HR 0.86, 95%CI 0.72-1.04; p=0.063) or interim OS (11.0 vs 11.1 months, respectively, HR 0.96, 95%CI 0.75-1.22) [34] . This study showed the efficacy of current agents for third-line therapy in mRCC. In addition, rechallenge with sunitinib in patients who progressed on prior sunitinib and another TKI or mTORi could be an option [35] .
Future perspectives in mRCC
Recently, a randomized phase III trial compared the activity of cabozantinib with that of everolimus in relapsed mRCC. Cabozantinib is an oral, small-molecule TKI that targets VEGFR as well as MET and AXL. The METEOR study was designed to evaluate the superiority of cabozantinib over everolimus in terms of PFS in patients with pre-treated mRCC; secondary endpoints were OS and response rate (RR) [36] . In this trial, median PFS in patients treated with cabozantinib was 7.4 months compared with 3.8 months in those treated with everolimus (p<0.001); there was a 42% reduction in disease progression or relapse with cabozantinib versus everolimus. A subgroup analysis confirmed the PFS benefit irrespective of MSKCC group and number of previous antiangiogenic therapies. The ORR was 21% and 5% in the cabozantinib and everolimus arms, respectively, (p<0.001). A more recent report also showed a survival benefit: median OS was 21.4 months with cabozantinib and 16.5 months with everolimus (HR 0.66, 95%CI 0.53-0.83; p=0.00026) [37] . These results certainly improve the range of agents avail-able, but the important question of the optimal sequence remains unanswered and in fact becomes more complicated. A sequential strategy including cabozantinib after nivolumab may be suitable for some patients previously treated with sunitinib or pazopanib. Moreover, a second TKI, such as axitinib or cabozantinib, could be an optional treatment to defer nivolumab to third-line therapy. The duration of response to a previous TKI, the aggressive behavior of the disease and the different toxicity profile of the available agents may be considered important factors in defining a sequential treatment strategy [38] . Unfortunately, molecular markers as predictors of response or resistance have not yet reached prime time.
Discussion and Conclusions
Nowadays, physicians have many effective options to treat mRCC. In the last decade, the introduction of new agents for this disease has improved survival and other clinical outcomes. Increasing recognition of the central role of the VEGF/VEGFR-pathway in the pathogenesis and development of RCC has provided and good rationale for inhibition of this pathway due to the frequent mutation of the VHL tumor suppressor gene in both clear cell RCC and in sporadic forms. This molecular signature renders RCC particularly dependent on angiogenesis and thus susceptible to angiogenesis inhibition with targeted agents. In this review we have presented details of clinical trials of targeted therapy in RCC and tried to define an optimal treatment sequence. For second-line treatment after failure of therapy with VEGFR-TKIs, continued inhibition of the VEGF/VEGR pathway or switching to an mTOR inhibitor is recommended. These two options have some different targets and completely different toxicity profiles, but comparable efficacy. However, new data from two randomized, controlled, phase III trials in which cabozantinib and nivolumab showed an OS benefit compared with everolimus will change options for second-line therapy in mRCC. When these agents become widely available, the current standards, axitinib and everolimus are expected to shift to become part of, and improve, the choice of potential agents for third-line therapy. Criteria for choosing a treatment when more than one valid option exists remain to be defined, but continuous development of active and effective agents is very likely to lead to further improvements in prognosis for patients with mRCC. Lack of direct comparative data on newer agents makes the choice difficult. However, in the current treatment paradigm it is unlikely that the "one sequence fits all" scenario is realistic. The sequence in which the available targeted agents are given needs to be carefully planned and individualized for each patient to optimize therapy and achieve the best outcomes. Factors to take into account include the safety profile of drugs, comorbidities of patients and tumor biology. Better knowledge of the mechanisms underlying renal cancer tumorigenesis could provide complementary information, identify predictors of response to drugs [39] , and help the physician to make the best choice for their patient.
